0001193125-26-111205
SEC filing营收大增63%但亏损扩大，ASSURE WCD放量驱动增长，商业化投入高企。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Revenue | $24,552K | $15,090K | +63% |
| Gross Profit | $12,906K | $6,547K | +97% |
| Gross Margin | 52.6% | 43.4% | +920 bps |
| Operating Income | -$34,765K | -$20,601K | +69% |
| Operating Margin | -141.6% | -136.5% | -510 bps |
| Net Income | -$34,166K | -$21,759K | +57% |
| Diluted EPS | -$0.61 | -$1.25 | — |
| Operating Cash Flow | -$62,983K | -$53,552K | +18% |
| Free Cash Flow | -$88,211K | -$69,099K | +28% |
营收增长主要由患者数量增加58%驱动，显示ASSURE WCD市场需求强劲。毛利率大幅提升920 bps至52.6%，得益于成本摊薄、制造改进及折旧年限延长。然而，SG&A费用激增79%至$42.7M，主要因人员扩张和上市相关成本，导致经营亏损扩大69%。净亏损$34.2M，同比扩大57%，但EPS改善至-$0.61（去年同期-$1.25），因加权平均股数增加。
公司作为单一经营分部运营，未披露分部数据。
| 项目 | 本期 | 上期/变化 |
|---|---|---|
| Cash & ST investments | $291,321K | +$53,726K |
| Total Debt | $42,261K | +$1,163K |
| Inventory | $6,829K | +$257K |
| Operating Cash Flow | -$62,983K | -$9,431K |
| Capex | $25,228K | +$9,681K |
| Free Cash Flow | -$88,211K | -$19,112K |